Terfenadine drug data and news

Terfenadine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.

Generic name Terfenadine
Brand Names/Synonyms Aldaban; Allerplus; Cyater; MDL-9918; Nebralin; RMI 9918; Seldane; Teldane; Teldanex; Terdin; Terfenadine; Terfex; Ternadin; Triludan
Indication For the treatment of allergic rhinitis; hay fever and allergic skin disorders
Sponsored links
Description Not Available
Pharmacology Terfenadine, an H1-receptor antagonist antihistamine, is similar in structure to astemizole and haloperidol, a butyrophenone antipsychotic. The active metabolite of terfenadine is fexofenadine.
Mechanism Of Action Terfenadine competes with histamine for binding at H1-receptor sites in the GI tract, uterus, large blood vessels, and bronchial muscle. This reversible binding of terfenadine to H1-receptors suppresses the formation of edema, flare, and pruritus resulting from histaminic activity. As the drug does not readily cross the blood-brain barrier, CNS depression is minimal.
Terfenadine News
(When available)
Dosage Forms Oral tablets
Drug_Category Antiarrhythmic Agents; Anti-allergic Agents; Antihistamines; ATC:R06AX12
Absorption On the basis of a mass balance study using 14C labeled terfenadine the oral absorption of terfenadine was estimated to be at least 70%
Interactions -->Interactions for Terfenadine:

Ketoconazole

Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. death, cardiac arrest, and ventricular arrhythmia including torsades de pointes. Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. Presence of unchanged terfenadine is associated with statistically significant prolongation of the QT and QTc intervals.Concomitant administration of ketoconazole and terfenadine is contraindicated.

Itraconazole

Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. One death has also been reported from foreign post- marketing sources. Concomitant administration of itraconazole and terfenadine is contraindicated.

Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.

Macrolides

Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. Although erythromycin measurably decreases the clearance of the terfenadine acid metabolite, its influence on terfenadine plasma levels is still under investigation. A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving erythromycin or troleandomycin.

Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. Studies to evaluate potential interactions of terfenadine with azithromycin are in progress.

Toxicity mild (e.g., headache, nausea, confusion); but adverse cardiac events including cardiac arrest, ventricular arrhythmias including torsades de pointes and QT prolongation have been reported; LD50=mg/kg (orally in mice)
Organisms Affected Humans and other mammals
Chemical IUPAC Name 4-[4-(hydroxy-diphenyl-methyl)-1-piperidyl]-1-(4-tert-butylphenyl)-butan-1-ol
Chemical Formula C32H41NO2
Molecular Weight 471.673 g/mol
Smiles String CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O
Melting Point 146.5-148.5°C
Water Solubility 0.001g/100ml
State white to off-white crystalline powder
LogP/Hphobicity 7.784
Isoelectric Point Not Available
Biotransformation Hepatic
Half Life 3.5 hours
Protein Binding [%] 70%
RxList Link RXlist
Sponsored links
Drug Reference http://www.drugs.com/cons/Terfenadine.html
http://www.rxlist.com/cgi/generic/terfen.htm
Drug Type Approved Drug
Accession No APRD00606
CAS Registry Number 50679-08-8
KEGG Compound ID C07463
PubChem ID SID:180732
PharmGKB ID Not Available
SwissProt ID Not Available
GenBank ID Not Available
Drug ID Number [DIN] 1913395

Home | About | Cancers | Treatment | Medications
Copyright onconews.org 2005.
All Rights Reserved.
Google
 
Web onconews.org